Zacutex lexipafant: Phase III

Zacutex did not meet its primary end point of a significant difference in the number of deaths observed within 28 days of treatment in 1,500 patients receiving either placebo or 10 or 100 mg/day of Zacutex intravenously for up to 7 days. ...